---
title: "Dogwood Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286420374.md"
datetime: "2026-05-14T12:52:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286420374.md)
  - [en](https://longbridge.com/en/news/286420374.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286420374.md)
generator: "portal-rs"
---

# Dogwood Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.15, beating the estimate of USD -0.2.

EBIT: As of FY2026 Q1, the actual value is USD -5.154 M.

### First Quarter 2026 Financial Results

#### Operating Expenses

Research and development expenses for the first quarter of 2026 were $2,669,779, compared to $2,436,998 for the first quarter of 2025, representing a $0.3 million increase primarily due to higher drug development costs for Halneuron® and increased salaries and personnel costs.General and administrative expenses for the first quarter of 2026 were $2,406,587, compared to $1,992,928 for the first quarter of 2025, with the $0.4 million increase mainly driven by higher salaries and related personnel costs, partially offset by a decrease in franchise fees.Total operating expenses for the first quarter of 2026 amounted to $5,076,366, up from $4,429,926 in the first quarter of 2025.

#### Net Loss and Per Share Data

Dogwood Therapeutics, Inc. reported a net loss attributable to common stockholders of -$4,986,614 for the first quarter of 2026, which is an improvement from -$12,181,614 for the first quarter of 2025.Basic and diluted net loss per share was -$0.15 for the first quarter of 2026, compared to -$8.45 for the first quarter of 2025.

### Balance Sheet Data

As of March 31, 2026, cash and cash equivalents were $13,227,839, an increase from $6,524,744 as of December 31, 2025.Total assets stood at $95,207,871 on March 31, 2026, compared to $90,171,237 on December 31, 2025.Total liabilities decreased to $14,584,519 on March 31, 2026, from $15,274,370 on December 31, 2025.Total stockholders’ equity increased to $80,623,352 as of March 31, 2026, from $74,896,867 as of December 31, 2025.

### Operational Metrics and Highlights

Dogwood Therapeutics, Inc. has enrolled 164 patients in its Halneuron® Phase 2b Chemotherapy Induced Neuropathic Pain (CINP) study.SP16 received Investigational New Drug (IND) approval from the FDA, with its study expected to begin enrolling in mid-2026 and fully funded by the National Cancer Institute.In January 2026, the company completed a financing of up to $26.9 million to advance Halneuron® through Phase 2b development, having received gross proceeds of $12.5 million.A Worldwide Development and Commercialization Partnership for Legacy Antiviral Assets was announced, with a potential value of up to $100 million to Dogwood Therapeutics, Inc. and its current and former shareholders.

### Outlook

Top-line results from the Halneuron® Phase 2b trial are anticipated in the fall of 2026, and the SP16 study is slated to commence enrollment in mid-2026.The company’s cash on hand of $13.2 million is projected to provide an operational runway into the fourth quarter of 2026.

### Related Stocks

- [DWTX.US](https://longbridge.com/en/quote/DWTX.US.md)

## Related News & Research

- [Dogwood Therapeutics to host virtual KOL event on Halneuron for chemotherapy-induced neuropathic pain](https://longbridge.com/en/news/296106790.md)
- [Public Storage announces R$ 0.41 per unit dividend for Q3 2026](https://longbridge.com/en/news/296635332.md)
- [REG - UIL Limited UIL Finance Ltd - Purchase of 2026 ZDP Shares](https://longbridge.com/en/news/296518280.md)
- [Corning sets Q3 2026 dividend at R$ 0.25 per unit](https://longbridge.com/en/news/296635714.md)
- [Baker Hughes declares Q3 2026 dividend of R$ 0.81 per unit](https://longbridge.com/en/news/296392545.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**